✦ LIBER ✦

MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

✍ Scribed by MA Joore; V Tjan Heijnen; JL Severens; A Novák; U Oron; M Pompen; BA Essers

Book ID: 119597053
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 71 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)66200-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transferability of Model-Based Economic

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

✍ Brigitte A.B. Essers; Shanley C. Seferina; Vivianne C.G. Tjan-Heijnen; Johan L. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB

PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

✍ BA Essers; V Tjan Heijnen; JL Severens; A Novák; U Oron; M Pompen; MA Joore 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

P18 Economic evaluation of adjuvant tras

P18 Economic evaluation of adjuvant trastuzumab in the treatment of early, HER2/neu-overexpressing breast cancer in Singapore

✍ G. De Lima Lopes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 32 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJ

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

✍ H AlOmar; AS Zazaa; M AlFayyadh; JA Ray 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

P176 Cardiac safety guidelines for the a

P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer

✍ M.S. Ewer; E.A. Perez; J. Baselga; R. Bell; D. Brutsaert; M. Marty; T. Pienkowsk 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB